128 related articles for article (PubMed ID: 19047117)
21. Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Fenn K; Maurer M; Lee SM; Crew KD; Trivedi MS; Accordino MK; Hershman DL; Kalinsky K
Clin Breast Cancer; 2020 Feb; 20(1):80-86. PubMed ID: 31570268
[TBL] [Abstract][Full Text] [Related]
22. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
23. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
Ali R; Brown W; Purdy SC; Davisson VJ; Wendt MK
Cell Death Dis; 2018 Sep; 9(10):976. PubMed ID: 30250119
[TBL] [Abstract][Full Text] [Related]
24. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Wang E; Sorolla A; Cunningham PT; Bogdawa HM; Beck S; Golden E; Dewhurst RE; Florez L; Cruickshank MN; Hoffmann K; Hopkins RM; Kim J; Woo AJ; Watt PM; Blancafort P
Oncogene; 2019 Jan; 38(1):140-150. PubMed ID: 30076412
[TBL] [Abstract][Full Text] [Related]
25. Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.
Yoshida H; Yoshimura H; Matsuda S; Ryoke T; Kiyoshima T; Kobayashi M; Sano K
Oncol Lett; 2018 Jun; 15(6):8627-8634. PubMed ID: 29805597
[TBL] [Abstract][Full Text] [Related]
26. Photo-immobilized EGF chemical gradients differentially impact breast cancer cell invasion and drug response in defined 3D hydrogels.
Fisher SA; Tam RY; Fokina A; Mahmoodi MM; Distefano MD; Shoichet MS
Biomaterials; 2018 Sep; 178():751-766. PubMed ID: 29452913
[TBL] [Abstract][Full Text] [Related]
27. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside.
Saburi E; Saburi A; Ghanei M
Caspian J Intern Med; 2017; 8(4):228-238. PubMed ID: 29201312
[TBL] [Abstract][Full Text] [Related]
28. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy.
Su YC; Burnouf PA; Chuang KH; Chen BM; Cheng TL; Roffler SR
Nat Commun; 2017 Jun; 8():15507. PubMed ID: 28593948
[TBL] [Abstract][Full Text] [Related]
29. The paradoxical functions of EGFR during breast cancer progression.
Ali R; Wendt MK
Signal Transduct Target Ther; 2017; 2():16042-. PubMed ID: 28435746
[TBL] [Abstract][Full Text] [Related]
30. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.
Matsuda N; Lim B; Wang X; Ueno NT
Expert Opin Investig Drugs; 2017 Apr; 26(4):463-479. PubMed ID: 28271910
[TBL] [Abstract][Full Text] [Related]
31. Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor.
Weitsman G; Mitchell NJ; Evans R; Cheung A; Kalber TL; Bofinger R; Fruhwirth GO; Keppler M; Wright ZVF; Barber PR; Gordon P; de Koning T; Wulaningsih W; Sander K; Vojnovic B; Ameer-Beg S; Lythgoe M; Arnold JN; Årstad E; Festy F; Hailes HC; Tabor AB; Ng T
Oncogene; 2017 Jun; 36(25):3618-3628. PubMed ID: 28166195
[TBL] [Abstract][Full Text] [Related]
32. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic mechanisms and factors in breast cancer treatment.
Castañeda-Gill JM; Vishwanatha JK
J Carcinog; 2016; 15():1. PubMed ID: 27013929
[TBL] [Abstract][Full Text] [Related]
34. The molecular landscape of premenopausal breast cancer.
Liao S; Hartmaier RJ; McGuire KP; Puhalla SL; Luthra S; Chandran UR; Ma T; Bhargava R; Modugno F; Davidson NE; Benz S; Lee AV; Tseng GC; Oesterreich S
Breast Cancer Res; 2015 Aug; 17():104. PubMed ID: 26251034
[TBL] [Abstract][Full Text] [Related]
35. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
[TBL] [Abstract][Full Text] [Related]
36. Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.
Brown WS; Wendt MK
Breast Cancer Res; 2014 Sep; 16(5):448. PubMed ID: 25255930
[TBL] [Abstract][Full Text] [Related]
37. Metronomics: towards personalized chemotherapy?
André N; Carré M; Pasquier E
Nat Rev Clin Oncol; 2014 Jul; 11(7):413-31. PubMed ID: 24913374
[TBL] [Abstract][Full Text] [Related]
38. Emerging targeted combinations in the management of breast cancer.
Lee RJ; Armstrong AC; Wardley AM
Breast Cancer (Dove Med Press); 2013; 5():61-72. PubMed ID: 24648759
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
[TBL] [Abstract][Full Text] [Related]
40. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.
Pories SE; Wulf GM
Breast Cancer (Dove Med Press); 2010 Jun; 2():37-44. PubMed ID: 24367165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
